Replies to post #192868 on Biotech Values

[DewDiligence]

BMRN—EMA will review Drisapersen for DMD under a standard (i.e. not accelerated) review:

http://finance.yahoo.com/news/biomarin-announces-ema-validates-maa-200100891.html